The new WHO classification of adrenal cortical proliferations reflects translational advances
in the fields of endocrine pathology, oncology and molecular biology. By adopting a …

Abstract Treatment for congenital adrenal hyperplasia (CAH) was introduced in the 1950s
following the discovery of the structure and function of adrenocortical hormones. Although …

Background Adrenal insufficiency in patients with classic 21-hydroxylase deficiency
congenital adrenal hyperplasia (CAH) is treated with glucocorticoid replacement therapy …

Purpose The hypothalamic–pituitary–adrenal (HPA) axis exerts many actions on the central
nervous system (CNS) aside from stress regulation. Glucocorticoids (GCs) play an important …

Hydrocortisone (HC) is the preferred drug in children with congenital adrenal hyperplasia
due to its lower potency as well as fewer reports of side effects. Fused deposition modelling …

Sex development relies on the sex-specific action of gene networks to differentiate the
bipotential gonads of the growing fetus into testis or ovaries, followed by the differentiation of …

The most common form of congenital adrenal hyperplasia is 21-hydroxylase deficiency
(21OHD), which in the classic (severe) form occurs in roughly 1: 16 000 newborns …

BACKGROUND Children with classic congenital adrenal hyperplasia (CAH) due to 21-
hydroxylase deficiency require treatment with glucocorticoids, usually at supraphysiologic …

Defined as congenital conditions in which development of chromosomal, gonadal, or
anatomic sex is atypical, differences or disorders of sex development (DSDs) comprise …

Background The prevalence of newborns with congenital adrenal hyperplasia (CAH)
detected by neonatal screening is well-described, but data including patients diagnosed …